Speech defects of parkinsonian patients. Effects of levodopa therapy on speech intelligibility.
D000433:1-Propanol / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005152:Facial Muscles / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D006801:Humans; D008046:Lip / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D010919:Placebos; D011352:Procyclidine / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use*; D013060:Speech / Q000187:drug effects*; D013064:Speech Disorders / Q000188:drug therapy / Q000209:etiology*
D000978:Antiparkinson Agents; D010919:Placebos; D011759:Pyrrolidines; D004295:Dihydroxyphenylalanine; D000433:1-Propanol; D011352:Procyclidine